236. 偽性副甲状腺機能低下症
[臨床試験数:6,薬物数:4(DrugBank:2),標的遺伝子数:20,標的パスウェイ数:28

Searched query = "Pseudohypoparathyroidism", "PHP", "PHP1a", "PHP1b", "PHP1c", "PHP2"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04240821
(ClinicalTrials.gov)
May 22, 202021/1/2020Theophylline for Treatment of PseudohypoparathyroidismOpen-Label Extension Study of Theophylline for Treatment of PseudohypoparathyroidismPseudohypoparathyroidism;Pseudohypoparathyroidism Type 1a;Albright Hereditary OsteodystrophyDrug: Theophylline ERAshley ShoemakerNULLEnrolling by invitation2 Years99 YearsAll34Phase 2United States